226 related articles for article (PubMed ID: 28891951)
1. Analysis of Class I Major Histocompatibility Complex Gene Transcription in Human Tumors Caused by Human Papillomavirus Infection.
Gameiro SF; Zhang A; Ghasemi F; Barrett JW; Nichols AC; Mymryk JS
Viruses; 2017 Sep; 9(9):. PubMed ID: 28891951
[TBL] [Abstract][Full Text] [Related]
2. High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells.
Bottley G; Watherston OG; Hiew YL; Norrild B; Cook GP; Blair GE
Oncogene; 2008 Mar; 27(12):1794-9. PubMed ID: 17828295
[TBL] [Abstract][Full Text] [Related]
3. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
4. High Levels of Class I Major Histocompatibility Complex mRNA Are Present in Epstein-Barr Virus-Associated Gastric Adenocarcinomas.
Ghasemi F; Gameiro SF; Tessier TM; Maciver AH; Mymryk JS
Cells; 2020 Feb; 9(2):. PubMed ID: 32098275
[TBL] [Abstract][Full Text] [Related]
5. Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14.
Cicchini L; Westrich JA; Xu T; Vermeer DW; Berger JN; Clambey ET; Lee D; Song JI; Lambert PF; Greer RO; Lee JH; Pyeon D
mBio; 2016 May; 7(3):. PubMed ID: 27143385
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
[TBL] [Abstract][Full Text] [Related]
7. Reduced MHC Class I and II Expression in HPV-Negative vs. HPV-Positive Cervical Cancers.
Evans AM; Salnikov M; Tessier TM; Mymryk JS
Cells; 2022 Dec; 11(23):. PubMed ID: 36497170
[TBL] [Abstract][Full Text] [Related]
8. CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8
Westrich JA; Vermeer DW; Silva A; Bonney S; Berger JN; Cicchini L; Greer RO; Song JI; Raben D; Slansky JE; Lee JH; Spanos WC; Pyeon D
Oncogene; 2019 Nov; 38(46):7166-7180. PubMed ID: 31417179
[TBL] [Abstract][Full Text] [Related]
9. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma.
Ritz U; Momburg F; Pilch H; Huber C; Maeurer MJ; Seliger B
Int J Oncol; 2001 Dec; 19(6):1211-20. PubMed ID: 11713591
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus 16-encoded E7 protein inhibits IFN-γ-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes.
Zhou F; Chen J; Zhao KN
J Gen Virol; 2013 Nov; 94(Pt 11):2504-2514. PubMed ID: 23956301
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins.
Georgopoulos NT; Proffitt JL; Blair GE
Oncogene; 2000 Oct; 19(42):4930-5. PubMed ID: 11039910
[TBL] [Abstract][Full Text] [Related]
12. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers.
Pyeon D; Newton MA; Lambert PF; den Boon JA; Sengupta S; Marsit CJ; Woodworth CD; Connor JP; Haugen TH; Smith EM; Kelsey KT; Turek LP; Ahlquist P
Cancer Res; 2007 May; 67(10):4605-19. PubMed ID: 17510386
[TBL] [Abstract][Full Text] [Related]
13. Differential MHC class II component expression in HPV-positive cervical cancer cells: implication for immune surveillance.
Zehbe I; Höhn H; Pilch H; Neukirch C; Freitag K; Maeurer MJ
Int J Cancer; 2005 Dec; 117(5):807-15. PubMed ID: 15981207
[TBL] [Abstract][Full Text] [Related]
14. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
Grasso F; Negri DR; Mochi S; Rossi A; Cesolini A; Giovannelli A; Chiantore MV; Leone P; Giorgi C; Cara A
Int J Cancer; 2013 Jan; 132(2):335-44. PubMed ID: 22700466
[TBL] [Abstract][Full Text] [Related]
15. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
16. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
17. RNA interference of human papillomavirus type 16 E7 increases HLA class I antigen expression in HaCaT-E7 cells.
Deng XM; Li W; Zhang X; Wang CX; Dong ZG; Zhang X; Zheng GX; Zhang XH; Zheng N; Wang LL; Du LT; Wang S
Int J Gynecol Cancer; 2011 Jan; 21(1):28-34. PubMed ID: 21330828
[TBL] [Abstract][Full Text] [Related]
18. High Level Expression of MHC-II in HPV+ Head and Neck Cancers Suggests that Tumor Epithelial Cells Serve an Important Role as Accessory Antigen Presenting Cells.
Gameiro SF; Ghasemi F; Barrett JW; Nichols AC; Mymryk JS
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31394808
[TBL] [Abstract][Full Text] [Related]
19. High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma.
Ressler S; Scheiden R; Dreier K; Laich A; Müller-Holzner E; Pircher H; Morandell D; Stein I; Viertler HP; Santer FR; Widschwendter A; Even J; Jansen-Dürr P; Capesius C; Zwerschke W
Clin Cancer Res; 2007 Dec; 13(23):7067-72. PubMed ID: 18056184
[TBL] [Abstract][Full Text] [Related]
20. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer.
Sasagawa T; Takagi H; Makinoda S
J Infect Chemother; 2012 Dec; 18(6):807-15. PubMed ID: 23117294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
